Cancer vaccine trials could start in England by autumn

After a deal with a firm behind one of the major Covid jabs, trials of personalized cancer vaccines in England are to be sped up.

The UK health secretary is to sign a Memorandum of Understanding with BioNTech on Friday to make sure the best possible treatments are available as soon as possible.

Cancer patients in England will be able to get early access to trials of new therapies, such as cancer vaccines, in the fall.

MRNA treatments are tailor-made for the individual and provide immune systems with genetic code from the specific cancer so it can attack only the tumours.

The partnership between BioNTech and the UK government could deliver 10,000 doses of personalized therapies to the UK by the year 2030.

When cancer is detected, we need to make sure the best possible treatments are available as quickly as possible.

They are perfect partners for a deal to work together on cancer vaccines because of their commitment to scientific advancement, innovation and cutting-edge scientific technology.

From as early as September, our patients will be among the first to participate in trials and tests to provide targeted, personalized and precision treatments using revolutionary new therapies to both treat the existing cancer and help stop it returning.

The UK successfully delivered Covid-19 vaccines so quickly because the National Health Service, academia, the regulator and the private sector worked together in an exemplary way, according to Prof Uur ahin.

Lessons Learned from the Covid-19 Pandemic are what led to the agreement. Drug development can be accelerated if everyone is on the same page. We are going to do the same for cancer patients.

ahin said that their goal is to accelerate the development of immunotherapies and vaccines using technologies they have been researching for over two decades. Hundreds of millions of people will be affected by various cancer types and infectious diseases as a result of the collaboration.

The potential to improve outcomes for patients and provide early access to innovative vaccines against infectious diseases is a result of this collaboration.